Skip to main content

Advertisement

SpringerLink
Log in

Prognostic value of ERCC1, ERCC2, XRCC1, and TP53 single nucleotide polymorphisms in patients with early-stage non-small cell lung cancer

  • Research Article
  • Published:
Tumor Biology

Abstract

Identification of biomarkers used for the prognostic evaluation of non-small cell lung cancer (NSCLC) patients is important. The aim of this study was to evaluate the potential prognostic value of XRCC1, ERCC1, ERCC2, and TP53 single nucleotide polymorphisms (SNPs) in completely resected NSCLC patients. In total, 130 patients, surgically treated for NSCLC between 2000 and 2012, were included. An analysis of SNPs from peripheral blood cells was performed by polymerase chain reaction. XRCC1 Arg399Gln, ERCC1 Asn118Asn, ERCC2 Lys751Gln, and TP53 Arg72Pro polymorphisms were evaluated in conjunction with clinical and pathological parameters and survival. Kaplan–Meier method and Cox regression analysis were used. Median age rate was 59.3, ranging between 36 and 78 years. Median relapse-free survival duration (RFS) was found as 46.2 months. In those with ERCC2 CC allele, median RFS was detected as 28.3 months (95 % confidence interval (CI), 20.8−35.8), 46.9 months in those with CT heterozygous (95 % CI, 18.6−75.2), and 80.1 months for those with TT mutant allel (95 % CI, 33.0−127.2). Median RFS was seen to be longer in mutant group and also statistically significant (P = 0.018). Additionally, upon evaluating CC normal group with CT + TT alleles including mutant alleles, median RFS was found as 56.5 months (95 % CI, 24.6−88.4) in CT + TT group, and this was statistically significant (P = 0.005) Also, median RFS was 15.1 months in those including ERCC2 CC allele and 56.5 months in CT + TT allele in the group with no adjuvant treatment (P = 0.001). In conclusion, our study showed that ERCC2/XPD polymorphism is an independent prognostic factor in operated NSCLC patients, and these findings should be supported with prospective studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29.

    Article  PubMed  Google Scholar 

  2. Mathiaux J, Le Morvan V, Pulido M, Jougon J, Bégueret H, Robert J. Role of DNA repair gene polymorphisms in the efficiency of platinum-based adjuvant chemotherapy for non-small cell lung cancer. Mol Diagn Ther. 2011;15(3):159–66.

    Article  CAS  PubMed  Google Scholar 

  3. Yin M, Yan J, Voutsina A, Tibaldi C, Christiani DC, Heist RS, et al. No evidence of an association of ERCC1 and ERCC2 polymorphisms with clinical outcomes of platinum-based chemotherapies in non-small cell lung cancer: a meta-analysis. Lung Cancer. 2011;72(3):370–7.

    Article  PubMed  Google Scholar 

  4. Ma H, Xu L, Yuan J, Shao M, Hu Z, Wang F, et al. Tagging single nucleotide polymorphisms in excision repair cross-complementing group 1 (ERCC1) and risk of primary lung cancer in a Chinese population. Pharmacogenet Genomics. 2007;17(6):417–23.

    Article  CAS  PubMed  Google Scholar 

  5. Kim M, Kang HG, Lee SY, Lee HC, Lee EB, Choi YY, et al. Comprehensive analysis of DNA repair gene polymorphisms and survival in patients with early stage non-small-cell lung cancer. Cancer Sci. 2010;101(11):2436–42.

    Article  CAS  PubMed  Google Scholar 

  6. Reed E. Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat Rev. 1998;24(5):331–44.

    Article  CAS  PubMed  Google Scholar 

  7. de Boer J, Hoeijmakers JH. Nucleotide excision repair and human syndromes. Carcinogenesis. 2000;21(3):453–60.

    Article  PubMed  Google Scholar 

  8. Lunn RM, Helzlsouer KJ, Parshad R, Umbach DM, Harris EL, Sanford KK, et al. XPD polymorphisms: effects on DNA repair capacity. Carcinogenesis. 2000;21(4):551–5.

    Article  CAS  PubMed  Google Scholar 

  9. Sung P, Bailly V, Weber C, Thompson LH, Prakash L, Prakash S. Human xeroderma pigmentosum group D geneencodes a DNA helicase. Nature. 1993;365(6449):852–5.

    Article  CAS  PubMed  Google Scholar 

  10. Wei SZ, Zhan P, Shi MQ, Shi Y, Qian Q, Yu LK, et al. Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis. Med Oncol. 2011;28(1):315–21.

    Article  CAS  PubMed  Google Scholar 

  11. Vilmar A, Sørensen JB. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature. Lung Cancer. 2009;64(2):131–9.

    Article  PubMed  Google Scholar 

  12. Giachino DF, Ghio P, Regazzoni S, Mandrile G, Novello S, Selvaggi G, et al. Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer. Clin Cancer Res. 2007;13(10):2876–81.

    Article  CAS  PubMed  Google Scholar 

  13. Gurubhagavatula S, Liu G, Park S, Zhou W, Su L, Wain JC, et al. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol. 2004;22(13):2594–601.

    Article  CAS  PubMed  Google Scholar 

  14. Oren M. Regulation of the p53 tumor suppressor protein. J Biol Chem. 1999;274(51):36031–4.

    Article  CAS  PubMed  Google Scholar 

  15. Gandara DR, Kawaguchi T, Crowley J, Moon J, Furuse K, Kawahara M, et al. Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics. J Clin Oncol. 2009;27(21):3540–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. de las Peñas R, Sanchez-Ronco M, Alberola V, Taron M, Camps C, Garcia-Carbonero R, et al. Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients. Ann Oncol. 2006;17(4):668–75.

    Article  PubMed  Google Scholar 

  17. Yao CY, Huang XE, Li C, Shen HB, Shi MQ, Feng JF, et al. Lack of influence of XRCC1 and XPD gene polymorphisms on outcome of platinum-based chemotherapy for advanced non small cell lung cancers. Asian Pac J Cancer Prev. 2009;10(5):859–64.

    PubMed  Google Scholar 

  18. Shiraishi K, Kohno T, Tanai C, Goto Y, Kuchiba A, Yamamoto S, et al. Association of DNA repair gene polymorphisms with response to platinum-based doublet chemotherapy in patients with non-small-cell lung cancer. J Clin Oncol. 2010;28(33):4945–52.

    Article  CAS  PubMed  Google Scholar 

  19. Isla D, Sarries C, Rosell R, Alonso G, Domine M, Taron M, et al. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol. 2004;15(8):1194–203.

    Article  CAS  PubMed  Google Scholar 

  20. Olaussen KA, Dunant A, Fouret P, Brambilla E, André F, Haddad V, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006;355(10):983–91.

    Article  CAS  PubMed  Google Scholar 

  21. Lord RV, Brabender J, Gandara D, Alberola V, Camps C, Domine M, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res. 2002;8(7):2286–91.

    CAS  PubMed  Google Scholar 

  22. Tibaldi C, Giovannetti E, Vasile E, Mey V, Laan AC, Nannizzi S, et al. Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res. 2008;14(6):1797–803.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The study was approved by the Ethical Board of the Meram Medical School of Selcuk University and performed with the financial support of the Scientific Research Project of Selcuk University (Project no: 11102028) in Konya, Turkey.

Conflicts of interest

None

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Meram Medical Faculty, Necmettin Erbakan University, Meram, 42100, Konya, Turkey

    Caglayan Geredeli, Mehmet Artac, Tunc Guler, Melih Cem Boruban, Lokman Koral & Mustafa Karaagac

  2. Department of Genetic, Meram Medical Faculty, Necmettin Erbakan University, Konya, Turkey

    Selman Yildirim & Ayse Gul Zamani

  3. Department of Medical Oncology, Medical Faculty, Dicle University, Diyarbakir, Turkey

    Ali Inal

  4. Department of Medical Oncology, School of Medicine, Ankara University, Ankara, Turkey

    Isa Dede & Ahmet Demirkazik

  5. Department of Thoracic Surgery, Meram Medical Faculty, Necmettin Erbakan University, Konya, Turkey

    Tamer Altinok

  6. Department of Thoracic Surgery, Medical Faculty, Gazi University, Ankara, Turkey

    Olgun Aribas

  7. Department of Medical Oncology, Medical Faculty, Akdeniz University, Antalya, Turkey

    Hakan Bozcuk

Authors
  1. Caglayan Geredeli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mehmet Artac
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Selman Yildirim
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ali Inal
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Isa Dede
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Tunc Guler
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Melih Cem Boruban
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Lokman Koral
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Mustafa Karaagac
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Ayse Gul Zamani
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Tamer Altinok
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Olgun Aribas
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Hakan Bozcuk
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Ahmet Demirkazik
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Caglayan Geredeli.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Geredeli, C., Artac, M., Yildirim, S. et al. Prognostic value of ERCC1, ERCC2, XRCC1, and TP53 single nucleotide polymorphisms in patients with early-stage non-small cell lung cancer. Tumor Biol. 36, 4279–4285 (2015). https://doi.org/10.1007/s13277-015-3066-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-015-3066-2

Keywords

Search

Navigation